Edition:
United Kingdom

DelMar Pharmaceuticals Inc (DMPI.OQ)

DMPI.OQ on NASDAQ Stock Exchange Capital Market

1.00USD
19 Apr 2018
Change (% chg)

$-0.04 (-3.85%)
Prev Close
$1.04
Open
$1.04
Day's High
$1.04
Day's Low
$0.99
Volume
64,559
Avg. Vol
101,296
52-wk High
$3.05
52-wk Low
$0.78

Select another date:

Tue, Apr 17 2018

BRIEF-DelMar Pharmaceuticals Presents Positive Updates on 2 Ongoing Clinical Trials with VAL-083 for Treatment of MGMT-unmethylated GBM

* DELMAR PHARMACEUTICALS PRESENTS POSITIVE UPDATES ON TWO ONGOING CLINICAL TRIALS WITH VAL-083 FOR TREATMENT OF MGMT-UNMETHYLATED GBM

BRIEF-Delmar Pharmaceuticals To Increase Number Of Authorized Shares Of Stock, Par Value Of $0.001, Per Share From 50 Mln Shares To 70 Mln Shares

* TO INCREASE NUMBER OF AUTHORIZED SHARES OF STOCK, PAR VALUE OF $0.001, PER SHARE FROM 50 MILLION SHARES TO 70 MILLION SHARES Source text: (https://bit.ly/2GWHkzx) Further company coverage:

BRIEF-Delmar Pharmaceuticals Q2 Loss Per Share $0.14

* DELMAR PHARMACEUTICALS ANNOUNCES SECOND QUARTER FISCAL YEAR 2018 FINANCIAL RESULTS

BRIEF-DelMar Pharmaceuticals Announces Fast Track Designation For VAL-083 In Recurrent Glioblastoma

* DELMAR PHARMACEUTICALS ANNOUNCES FAST TRACK DESIGNATION FOR VAL-083 IN RECURRENT GLIOBLASTOMA

BRIEF-Delmar Pharmaceuticals' interim CEO Saiid​ ‍Zarrabian reports purchase of 60,900 shares of co's common stock on Nov 14

* Delmar Pharmaceuticals Inc interim CEO Saiid​ ‍Zarrabian reports purchase of 60,900 shares of co's common stock on nov 14 - SEC Filing Source text: (http://bit.ly/2hydYIN) Further company coverage:

BRIEF-Delmar Pharmaceuticals names Saiid Zarrabian interim CEO

* Delmar Pharmaceuticals appoints Saiid Zarrabian as interim chief executive officer

Select another date: